Log In Get Started
Press Releases April 24, 2026 04:05 PM

Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

Intellia to Release Phase 3 Data for CRISPR-based Hereditary Angioedema Treatment

By Derek Hwang NTLA
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
NTLA

Intellia Therapeutics announced it will report topline Phase 3 clinical trial data of its CRISPR gene editing candidate lonvoguran ziclumeran for hereditary angioedema on April 27, 2026, hosting a webcast to discuss results. This represents the world’s first Phase 3 readout for an in vivo CRISPR gene editing therapy, advancing Intellia’s mission to develop potentially curative treatments.

Key Points

  • Intellia is the first to report Phase 3 clinical data for an in vivo CRISPR gene editing therapy, marking a milestone in gene editing therapeutics.
  • The Phase 3 HAELO trial tests lonvoguran ziclumeran in hereditary angioedema, a rare genetic disease, potentially offering a transformative treatment option.
  • Positive trial results could set a new standard in biopharmaceuticals targeting root causes of severe diseases using gene editing technologies.
  • World’s first Phase 3 readout for an in vivo CRISPR gene editing candidate
  • Company to host webcast to discuss data at 8:00 a.m. ET on April 27, 2026

CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the company will report topline clinical data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) on Monday, April 27, 2026 and will host a webcast at 8:00 a.m. ET to discuss the data.

To join the webcast, please visit the Events page of the Investors & Media section on Intellia’s website at intelliatx.com. A replay of the webcast will be available for approximately 90 days.

About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
[email protected]

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
[email protected]


Risks

  • Clinical trial results may not meet efficacy or safety endpoints, impacting future development and regulatory approval.
  • Regulatory scrutiny and challenges around novel gene editing therapies could delay or restrict market access.
  • Market acceptance uncertainty exists as gene editing treatments are novel with unknown long-term safety and reimbursement landscapes.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026